Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Weekly News Recap #Phispers
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40503
Submission : 2024-09-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38773
Submission : 2023-08-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40481
Submission : 2024-12-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40123
Submission : 2024-07-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40378
Submission : 2024-12-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39465
Submission : 2024-02-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40115
Submission : 2024-07-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39655
Submission : 2024-03-17
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39611
Submission : 2024-02-28
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40166
Submission : 2024-06-27
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and solutions, offering global API and preparation production services. Co-founded by...
Vtides Life Sciences: Pioneering Peptide API Development & Manufacturing in State-of-the-art GMP Facilities Since 2024.
About the Company : Vtides Life Sciences Pvt Ltd specializes in the design and synthesis of complex peptides, employing advanced chemical strategies such as microwave-assisted solid-phase synthesis. T...
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...
About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Sumar Biotech LLP, registered in January 2018, is a startup approved by the Gujarat State Biotechnology Mission. It was founded by emerging entrepreneurs and a team of young yet ex...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Brand Name: Mounjaro
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspen Announces Local Availability of Lilly’s Mounjaro
Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Product Name : Mounjaro
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Details:
The net proceeds from the offering will be used to fund the developement of Vyleesi (bremelanotide acetate), which is being evaluated in mid-stage clinical trial studies for the treatment of obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Alliance Global Partners
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 07, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Alliance Global Partners
Deal Size : $23.0 million
Deal Type : Public Offering
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Details : The net proceeds from the offering will be used to fund the developement of Vyleesi (bremelanotide acetate), which is being evaluated in mid-stage clinical trial studies for the treatment of obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Undisclosed
May 07, 2025
Details:
Vyleesi (bremelanotide) is a melanocortin receptor agonist (MCR), which is being evaluated in combination with tirzepatide for obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Sees Positive Appetite Suppression in Obesity Study with Bremelanotide Combo
Details : Vyleesi (bremelanotide) is a melanocortin receptor agonist (MCR), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
April 17, 2025
Details:
Nimacimab is a first-in-class peripheral CB1-inhibiting antibody, being studied with the dual GLP-1/GIP agonist, tirzepatide for obesity.
Lead Product(s): Nimacimab,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Lead Product(s) : Nimacimab,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Skye Shows 30% Weight Loss in Preclinical with Nimacimab Combo
Details : Nimacimab is a first-in-class peripheral CB1-inhibiting antibody, being studied with the dual GLP-1/GIP agonist, tirzepatide for obesity.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 15, 2025
Details:
Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin's MC4R Agonist Bremelanotide with GLP-1/GIP Tirzepatide Hits Ph 2 Goal
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
March 31, 2025
Details:
Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Brand Name: Mounjaro
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2025
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eli Lilly Launches Weight-Loss Drug Mounjaro in India After Drug Regulator Approval
Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Product Name : Mounjaro
Product Type : Peptide
Upfront Cash : Inapplicable
March 20, 2025
Details:
ARO-INHBE is a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.
Lead Product(s): ARO-INHBE,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: ARO-INHBE
Study Phase: Phase I/ Phase IIProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2025
Lead Product(s) : ARO-INHBE,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Showcases RNAi Candidates for Obesity, Metabolic Disorders
Details : ARO-INHBE is a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.
Product Name : ARO-INHBE
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 06, 2025
Details:
Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Vyleesi
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2025
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.
Product Name : Vyleesi
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2025
Details:
Zepbound (tirzepatide) injection is a first obstructive sleep apnea in adults with obesity treatment of its kind that activates both GIP/GLP-1 hormone receptors.
Lead Product(s): Tirzepatide
Therapeutic Area: Sleep Brand Name: Zepbound
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Zepbound® (Tirzepatide) for Obstructive Sleep Apnea in Adults with Obesity
Details : Zepbound (tirzepatide) injection is a first obstructive sleep apnea in adults with obesity treatment of its kind that activates both GIP/GLP-1 hormone receptors.
Product Name : Zepbound
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Details:
Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Brand Name: DehydraTECH-tirzepatide
Study Phase: Phase IProduct Type: Peptide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.
Product Name : DehydraTECH-tirzepatide
Product Type : Peptide
Upfront Cash : Inapplicable
December 19, 2024
16 Jul 2025
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/et-graphics-weight-loss-drugs-tirzepatide-semaglutide-dominate-india-misuse-fears-rise/articleshow/122528364.cms
08 Jul 2025
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/mounjaro-crosses-rs-50-cr-in-india-in-90-days-as-wegovy-joins-fray/articleshow/122305335.cms
07 Jul 2025
// BUSINESS STD
https://www.business-standard.com/industry/news/wegovy-mounjaro-sales-rise-intensifies-anti-obesity-drug-battle-125070701101_1.html
03 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/03/3110163/0/en/Remote-Pharmacy-Releases-2025-Availability-Update-on-GLP-1-Weight-Loss-Solutions-and-Consumer-Interest-in-Semaglutide-Tirzepatide.html
27 Jun 2025
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/eli-lilly-to-roll-out-diabetes-medicine-in-prefilled-pen/articleshow/122097854.cms
20 Jun 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/scholar-rocks-drug-helps-preserve-lean-mass-mid-stage-trial-2025-06-18/
Global Sales Information
Dosage Form : Solution for injection
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 50.14
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Solution for injection in a pre-...
Dosage Strength : 2.5 mg
Price Per Pack (Euro) : 200.54
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Solution for injection in a pre-...
Dosage Strength : 5 mg
Price Per Pack (Euro) : 200.54
Published in :
Country : Norway
RX/OTC/DISCN :
Market Place
Reply
11 Jul 2025
Reply
15 May 2025
Reply
21 Feb 2025
Reply
23 Jan 2025
Reply
23 Nov 2024
Reply
28 Oct 2024
Reply
25 Oct 2024
Reply
03 Aug 2024
Reply
06 Apr 2024
Reply
17 Jan 2024
Patents & EXCLUSIVITIES
ABOUT THIS PAGE